Description: Discuss policyholder behaviors that evolve throughout the life cycle of a typical VA annuitant, with supporting data from industry-level experience studies during this interaction session. The following behavior assumptions and their implication under accounting/regulatory requirements will be covered: - Separate account/fixed account allocation and transfers - Deposits - Surrenders - Withdrawals - Income utilization - Mortality By attending the session, you will: - Identify policyholder behaviors that would transform at different stages of life cycle. - Understand key aspects of industry-level policyholder behavior experience. - Form a dynamic view in the assumption setting.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: The time has arrived for ASU 2018-12, otherwise known as Long-Duration Targeted Improvements (LDTI). For health insurance products, the ASU will require considerable efforts to make the necessary changes to valuation systems, procedures, assumptions, and/or methodologies in order to be in compliance. This session is designed to cover LDTI implications specific to carriers of long-term care and supplemental health products, including changes to how attained age rated products will be approached, allocating and discounting the claim liability (IBNR), and how the treatment of Profits Followed by Losses (PFBL) will evolve under LDTI. By attending this session, you will be able to: • Understand LDTI’s key impacts on long-duration health insurance products. • Recognize the treatment of attained age rated products under LDTI. • Comprehend the requirements of allocating the claim liability to cohorts. • Grasp the requirements pertaining to the discounting of the claim liability. • Understand how PFBL will evolve under the new standard.

Description: Dive into an overview of potential customer value propositions, trends in consumer acceptance and adoption, solving the data portability issue, potential impacts of emerging partner ships with OEMs and more within the auto insurance industry during our latest webcast. Experience interactive dialogue that will allow another dimension of thinking as industry experts provide insights and expertise. Throughout this webcast, you can expect developments in the personal lines automotive telematics-based insurance landscape that will develop a further understanding of the present and future of this industry.

Description: Session 9B: Actuaries and Technology: Perspectives on Actuarial Workflow Automation The life insurance industry has experienced unprecedented growth in modernization efforts, with special attention paid to automating actuarial workflows. Companies are creating processes that are more scalable and maintainable, helping actuaries meet strict deadlines and deliver meaningful information to stakeholders. Discuss practical examples of automation, potential compositions of the modern actuarial toolkit, and different ways actuaries and technology teams interact during implementation and production states. Examine how automation can help actuarial teams shift from a quarterly to a monthly valuation process by overcoming challenges in traditional actuarial processes-long run times, the need for highly specialized legacy software skills, and inadequate control. Shifting to a monthly schedule can increase alignment on company objectives, deepen insurers' understanding of their business, and improve strategic decision-making. Leave with new ways of thinking about technology, from day-to-day best practices to full-scale actuarial transformation. By attending the session, you will: - Explain and understand the benefits of automating actuarial workflows with the purpose of operating on a monthly, rather than quarterly basis. - Describe the categories and purposes of several kinds of automation and supporting tools that might be used to accomplish this. - Understand different actuarial IT operating models and consider the application of such strategies at your organization. - Identify best practices for implementing automation based on the presented case studies.

Description: Term products exhibit a wide range of behavior as policyholders can elect different term periods and conversion options. While term products have been around for decades, it's only recently that longer level term products are reaching the end of the level term period. Term conversions have historically been an afterthought and are rarely modeled. Discuss the use of predictive modeling techniques such as LASSO regression and cross-validation to build models for level term lapses and post-level term shock lapses, as well as the extrapolation of experience for shorter term products to longer term products (e.g., extrapolating 20-year term experience and applying to 30-year term). Explore the use of traditional techniques to develop term conversion rates and a framework for modeling the assumption. Challenges and limitations of setting lapse and conversion rates will be discussed. By attending the session, you will: - Understand the complexities of term policyholder behavior. - Understand the challenges in developing and implementing assumptions for lapses and conversions. - Understand the application of traditional and predictive modeling techniques for term policyholder behavior.

Description: Open source programming languages have become a common part of the actuarial toolkit over the years. Using tools like R and Python, highly technical actuaries can automate onerous processes, easily work with massive amounts of data, create models and generate reports. Although these tools excel at turbo-charging analysts, it can be difficult for benefits to inure to the rest of the organization given the learning curve (“Can’t you just put this in Excel?”), control risks (“So your entire process could break overnight if some random person in Nebraska changes something?”), and internal IT environments. Listen in on a panel discussion where presenters share their personal stories of working with open source in a production setting. Hear about real world business problems, how open source tools were used, what risks were present, how they were overcome and the final business result.

Description: Come discuss how to treat experience that is impacted by COVID (e.g., 2020+), as well as expected experience moving forward in terms of excess deaths related to COVID and non-COVID topics. Expect to also cover how the COVID period has impacted lapse/surrender behavior and trends in recent industry mortality and lapse studies that have been conducted including areas where individual companies typically have limited data. You will learn about various techniques of adjusting experience for the impact of COVID and the considerations in using such experience and setting a best-estimate assumption going forward. For mortality, the discussion will include both base mortality as well as future mortality improvement and the intersection of both of these.Explore an understanding of available data to supplement their experience in areas where they may have limited internal experience

Description: With mortality rates significantly higher in 2020 and 2021 due to the COVID-19 pandemic, actuaries that rely on historical experience cannot properly craft assumptions about the future due to the recent excess deaths. This webcast focuses on the practicality of using pandemic mortality experience, as well as how to overcome the practical challenges of that data implementation. Explore an overview of different approaches used by institutions in the U.S., Canada and UK and an observation of industry survey responses. There will also be a comparison to recent SOA expert opinion surveys and short term impacts on the future of U.S. mortality.

Description: The most recent U.S. population data released by the Centers for Disease Control and Prevention (CDC) and from the U.S. Census at year-end 2021 includes the first ten months of the COVID-19 pandemic in the U.S. While we know the pandemic has had significant impacts on both the U.S. population and insured population mortality, we also see increased mortality due to many other non-COVID causes of death. Where are the biggest changes and what does this non-COVID excess mortality mean over the next few years? Take part as an expert panel hosts an interactive discussion to examine data from general population as well as from both individual life and group life experience studies to explore how these changes might spur innovation in underwriting, assumption setting and pricing.